Alnylam Announces 33% Staff Cut, Will Focus Internally On Two Lead RNAi Programs

The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.